NovaSterilis

3109 N. Triphammer Road
Lansing, NY 14882
607.330.2772
novasterilis.com

Press Release

David C. Burns Appointed President and CEO of NovaSterilis

ITHACA, NY, January 27th, 2002 – **NovaSterilis** today appointed **David C. Burns as its President and CEO. Mr. Burns** is assuming responsibility for the company, which designs, manufactures, licenses, and distributes systems for sterilizing sensitive medical and drug delivery devices. The **NovaSterilis** technology, supercritical carbon dioxide sterilization (SCDS), is superior to current sterilization techniques for thermally and hydrolytically labile materials used in today's biomedical industry.

Mr. Burns brings to **NovaSterilis** over 20 years of management experience in engineering-based companies. During 1989-1993, he served as Program Manager at GE Astro Space, where he oversaw programs totaling $140M, with complete P&L responsibility, and provided the leadership in capturing several opportunities in the Japanese and Asian marketplaces ranging from $125-350M. Between 1993 and 1996, **Burns** held the position of Vice President for Business Development at Space Systems/Loral, where he was responsible for winning new business in the Philippines, Japan, Indonesia, Thailand and Hong Kong. During that time, backlog for SS/L grew from $450M to greater than $1.4B. As President and CEO of Ithaco Space Systems between 1996 and 1999, **Burns** saw revenues increase 80%, backlog triple, and income rise 300%, culminating in the sale of Ithaco for $33.5M in 1999, an increase of $29M from the previous acquisition by Kohlberg and Company, less than 3 years earlier.

"We are extremely pleased to have **David** as our new President and CEO," said **Tony Eisenhut, President and CEO of KensaGroup**, which launched **NovaSterilis** from an early stage university invention. "**David** brings to **NovaSterilis** proven expertise and accomplishments in building, managing, and increasing the value of companies from startup to multinational. He has precisely the experience and skills required to take **NovaSterilis** forward as a leader in medical sterilization."

SCDS is both an enabling and a displacing technology: Its primary advantage is its compatibility with biodegradable polymers and other materials that cannot tolerate existing sterilization methods. SCDS is capable of inactivating a wide variety of microbiological contaminants, without altering the structural and physical properties of thermally and hydrolytically labile materials. Carbon dioxide is a natural, non-reactive gas that is chemically inert, environmentally sound, and very inexpensive, resulting in lower capital and operating costs.

Located in Ithaca, NY, **NovaSterilis** is an outgrowth of the highly visible research conducted by Professor Robert S. Langer and his collaborators at MIT.